Afjal H. Miah
Research Subjects
Afjal H. Miah has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Glenn A. Burley
Department of Pure and Applied Chemistry University of Strathclyde Glasgow UK
3 shared publications - David J. Battersby
Medicinal Chemistry GSK Medicines Research Centre Gunnels Wood Road SG1 2NY Stevenage Hertfordshire United Kingdom
2 shared publications Diana Klimaszewska
Discovery Biology and Screening, GSK, Stevenage, SG1 2NY, UK
2 shared publications- John D. Harling
Medicinal Chemistry GSK Medicines Research Centre Gunnels Wood Road SG1 2NY Stevenage Hertfordshire United Kingdom
2 shared publications Jonathan M. Percy
WestCHEM Department of Pure and Applied Chemistry, University of Strathclyde, 295 Cathedral Street, Glasgow G1 1XL, United Kingdom
2 shared publications- Rebecca Stevens
Modality Platform Technologies, GSK, Stevenage, SG1 2NY, UK
2 shared publications
Latest Publications
- 29 June 2026
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 21 (7) , 1798-1817
A Systematic Direct-to-Biology Approach Identified Potent Cereblon HaloPROTACs
HaloTags have emerged as versatile tools for protein labeling, investigating target biology, and facilitating targeting protein degradation using synthetic ligands called HaloPROTACs. These chemical tools are heterobifunctional molecules consisting of a chloroalkane derivative linked to E3 ubiquitin ligase-recruiting moieties to artificially induce proximity between the ligase and target protein of interest fused to the HaloTag construct. Through this induced proximity, HaloPROTACs can facilitate temporal- and dose-dependent degradation of target proteins, enabling efficient cellular protein knockdown without the need for target-specific ligands. In this study, we developed cereblon (CRBN)-recruiting HaloPROTACs through the use of plate-based high-throughput synthesis and direct-to-biology screening. We evaluated over 100 structurally diverse CRBN HaloPROTACs in an FAK-tagged cell line, resulting in the identification of highly potent tools. Notably, HaloPROTACs incorporating dihydrouracil CRBN binders exhibited superior potency and selectivity compared with their IMiD-based counterparts. These newly developed CRBN-based HaloPROTACs represent a valuable addition to the existing HaloPROTAC toolkit, offering enhanced capabilities for advancing research on targeted protein degradation.
- 29 June 2026
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 21 (7) , 1798-1817
A Systematic Direct-to-Biology Approach Identified Potent Cereblon HaloPROTACs
HaloTags have emerged as versatile tools for protein labeling, investigating target biology, and facilitating targeting protein degradation using synthetic ligands called HaloPROTACs. These chemical tools are heterobifunctional molecules consisting of a chloroalkane derivative linked to E3 ubiquitin ligase-recruiting moieties to artificially induce proximity between the ligase and target protein of interest fused to the HaloTag construct. Through this induced proximity, HaloPROTACs can facilitate temporal- and dose-dependent degradation of target proteins, enabling efficient cellular protein knockdown without the need for target-specific ligands. In this study, we developed cereblon (CRBN)-recruiting HaloPROTACs through the use of plate-based high-throughput synthesis and direct-to-biology screening. We evaluated over 100 structurally diverse CRBN HaloPROTACs in an FAK-tagged cell line, resulting in the identification of highly potent tools. Notably, HaloPROTACs incorporating dihydrouracil CRBN binders exhibited superior potency and selectivity compared with their IMiD-based counterparts. These newly developed CRBN-based HaloPROTACs represent a valuable addition to the existing HaloPROTAC toolkit, offering enhanced capabilities for advancing research on targeted protein degradation.
- Open Access
- 23 January 2025
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 16 (9) , 3938-3945
Stereoselective synthesis of atropisomeric amides enabled by intramolecular acyl transfer
A stereoselective strategy to make C–N atropisomeric amides based on intramolecular acyl transfer via a tethered Lewis basic pyridine or tertiary amine group is reported.
- 23 January 2025
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 16 (9) , 3938-3945
Open AccessStereoselective synthesis of atropisomeric amides enabled by intramolecular acyl transfer
A stereoselective strategy to make C–N atropisomeric amides based on intramolecular acyl transfer via a tethered Lewis basic pyridine or tertiary amine group is reported.
- 23 December 2024
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 16 (3) , 1141-1150
Expanding the reaction toolbox for nanoscale direct-to-biology PROTAC synthesis and biological evaluation
High-throughput chemistry (HTC) and direct-to-biology (D2B) platforms allow for plate-based compound synthesis and biological evaluation of crude mixtures in cellular assays. The rise of these workflows has rapidly accelerated drug-discovery programs in the field of targeted protein degradation (TPD) in recent years by removing a key bottleneck of compound purification. However, the number of chemical transformations amenable to this methodology remain minimal, leading to limitations in the exploration of chemical space using existing library-based approaches. In this work, we expanded the toolbox by synthesising a library of degraders in D2B format. First, reaction conditions are established for performing key medicinal chemistry transformations, including reductive amination, SNAr, palladium-mediated cross-coupling and alkylation, in D2B format. Second, the utility of these alternative reactions is demonstrated by rapidly identifying developable PROTACs for a range of protein targets.
- 23 December 2024
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 16 (3) , 1141-1150
Expanding the reaction toolbox for nanoscale direct-to-biology PROTAC synthesis and biological evaluation
High-throughput chemistry (HTC) and direct-to-biology (D2B) platforms allow for plate-based compound synthesis and biological evaluation of crude mixtures in cellular assays. The rise of these workflows has rapidly accelerated drug-discovery programs in the field of targeted protein degradation (TPD) in recent years by removing a key bottleneck of compound purification. However, the number of chemical transformations amenable to this methodology remain minimal, leading to limitations in the exploration of chemical space using existing library-based approaches. In this work, we expanded the toolbox by synthesising a library of degraders in D2B format. First, reaction conditions are established for performing key medicinal chemistry transformations, including reductive amination, SNAr, palladium-mediated cross-coupling and alkylation, in D2B format. Second, the utility of these alternative reactions is demonstrated by rapidly identifying developable PROTACs for a range of protein targets.
- 10 April 2024
- Published by Royal Society of Chemistry (RSC) in Chemical Society Reviews
- Vol. 53 (10) , 4838-4861
Innovative, combinatorial and high-throughput approaches to degrader synthesis
Targeted protein degraders such as PROTACs and molecular glues are a rapidly emerging therapeutic modality within industry and academia. Degraders possess unique mechanisms of action that lead to the removal of specific proteins by co-opting the cell's natural degradation mechanisms via induced proximity. Their optimisation thus far has often been largely empirical, requiring the synthesis and screening of a large number of analogues. In addition, the synthesis and development of degraders is often challenging, leading to lengthy optimisation campaigns to deliver candidate-quality compounds. This review highlights how the synthesis of degraders has evolved in recent years, in particular focusing on means of applying high-throughput chemistry and screening approaches to expedite these timelines, which we anticipate to be valuable in shaping the future of degrader optimisation campaigns.
- 10 April 2024
- Published by Royal Society of Chemistry (RSC) in Chemical Society Reviews
- Vol. 53 (10) , 4838-4861
Innovative, combinatorial and high-throughput approaches to degrader synthesis
Targeted protein degraders such as PROTACs and molecular glues are a rapidly emerging therapeutic modality within industry and academia. Degraders possess unique mechanisms of action that lead to the removal of specific proteins by co-opting the cell's natural degradation mechanisms via induced proximity. Their optimisation thus far has often been largely empirical, requiring the synthesis and screening of a large number of analogues. In addition, the synthesis and development of degraders is often challenging, leading to lengthy optimisation campaigns to deliver candidate-quality compounds. This review highlights how the synthesis of degraders has evolved in recent years, in particular focusing on means of applying high-throughput chemistry and screening approaches to expedite these timelines, which we anticipate to be valuable in shaping the future of degrader optimisation campaigns.
- Open Access
- 1 September 2023
- Published by American Chemical Society (ACS) in ChemRxiv
An Integrated Direct-to-Biology Platform for the Nanoscale Synthesis and Biological Evaluation of PROTACs
Proteolysis targeting chimeras (PROTACs) are heterobifunctional molecules that co opt the cell’s natural proteasomal degradation mechanisms to selectively tag and degrade undesired proteins. However, a challenge associated with PROTACs is the difficult optimisation required to identify new degraders, thus the development of high-throughput platforms for their synthesis and biological evaluation is required. In this study, we establish an ultra high-throughput experimentation (ultraHTE) platform for PROTAC synthesis, followed by direct addition of the crude reaction mixtures to cellular degradation assays without any purification. This ‘Direct-to-Biology’ (D2B) approach was validated, then exem-plified in a medicinal chemistry campaign to identify novel BRD4 PROTACs from a BRD4-binding scaffold previously unexplored for targeted protein degradation. Using the D2B platform, the synthesis of over 600 PROTACs was carried out in a 1536-well plate and subsequent biological evaluation of these candidates was performed by a single scientist in less than one month, to identify a set of picomolar BRD4 degraders. Due to its ability to hugely accelerate the optimisation of new degraders, we anticipate our platform to transform the synthesis and testing of PROTACs.
- 1 September 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessAn Integrated Direct-to-Biology Platform for the Nanoscale Synthesis and Biological Evaluation of PROTACs
Proteolysis targeting chimeras (PROTACs) are heterobifunctional molecules that co opt the cell’s natural proteasomal degradation mechanisms to selectively tag and degrade undesired proteins. However, a challenge associated with PROTACs is the difficult optimisation required to identify new degraders, thus the development of high-throughput platforms for their synthesis and biological evaluation is required. In this study, we establish an ultra high-throughput experimentation (ultraHTE) platform for PROTAC synthesis, followed by direct addition of the crude reaction mixtures to cellular degradation assays without any purification. This ‘Direct-to-Biology’ (D2B) approach was validated, then exem-plified in a medicinal chemistry campaign to identify novel BRD4 PROTACs from a BRD4-binding scaffold previously unexplored for targeted protein degradation. Using the D2B platform, the synthesis of over 600 PROTACs was carried out in a 1536-well plate and subsequent biological evaluation of these candidates was performed by a single scientist in less than one month, to identify a set of picomolar BRD4 degraders. Due to its ability to hugely accelerate the optimisation of new degraders, we anticipate our platform to transform the synthesis and testing of PROTACs.
- 1 October 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 25 (20) , 5327-5340
Identification of pyrazolopyrimidine arylsulfonamides as CC-chemokine receptor 4 (CCR4) antagonists
- 1 October 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 25 (20) , 5327-5340
Identification of pyrazolopyrimidine arylsulfonamides as CC-chemokine receptor 4 (CCR4) antagonists
- Open Access
- 2 March 2005
- Published by Wiley in ChemInform
- Vol. 36 (13)
A Potentially Divergent and Rapid Route to Analogues of Deoxycyclitols, Pentopyranoses, 6‐Deoxyhexoses, and Hexoses
For Abstract see ChemInform Abstract in Full Text.
- 2 March 2005
- Published by Wiley in ChemInform
- Vol. 36 (13)
Open AccessA Potentially Divergent and Rapid Route to Analogues of Deoxycyclitols, Pentopyranoses, 6‐Deoxyhexoses, and Hexoses
For Abstract see ChemInform Abstract in Full Text.